Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Category: CTEGD Blog

UGA receives life sciences industry awards from Georgia Bio

By Allyson Mann

The University of Georgia was well represented at the Georgia Bio Awards, with five awards recognizing programs either at or affiliated with the university. The awards were presented by Georgia Bio, the association for Georgia’s life sciences industry, at its 2018 annual awards dinner Feb. 15 in Atlanta.

This year, two UGA units—the Center for Vaccines and Immunology and the Center for Tropical & Emerging Global Diseases—received awards, as did ArunA Biomedical, a biotechnology company that grew out of faculty research. The university also is affiliated with two additional award winners, the Georgia Clinical & Translational Science Alliance and the National Science Foundation Engineering Research Center for Cell Manufacturing Technologies.

Georgia Bio members include pharmaceutical, biotechnology and medical device companies; medical centers; universities and research institutes; government groups; and other business organizations involved in the development of life sciences-related products and services.

“Improving human health and welfare is a vitally important part of UGA’s land-grant mission in the 21st century, and we have worked hard to expand our capabilities in this regard,” said UGA Vice President for Research David Lee. “It is gratifying to receive these awards from Georgia Bio, as they testify to the impact of our programs and the success of the faculty responsible for them.”

Ted M. Ross accepted the Phoenix Award, presented jointly to the Center for Vaccines and Immunology (CVI) and Sanofi Pasteur. Recipients of the Phoenix Award, sponsored by the Metro Atlanta Chamber and celebrating the best in industry and academic collaboration, have forged academic and industry relationships that drive translation and lead to new treatments and cures. Ross is Georgia Research Alliance Eminent Scholar of Infectious Disease and director of CVI, which is dedicated to improving human and animal health through new and improved vaccine technologies.

Two Deals of the Year Awards were presented in recognition of financial or commercial transactions that are significant to the development of Georgia’s life sciences industry. The first was awarded to the Georgia Clinical & Translational Science Alliance (Georgia CTSA), a team comprising UGA, Emory University, the Morehouse School of Medicine and the Georgia Institute of Technology that will train new investigators and develop the infrastructure for accelerating research-based improvements in clinical care and outcomes for the benefit of Georgia citizens. Bradley Phillips, the Millikan-Reeve Professor of Pharmacy and director of the Clinical and Translational Research Unit, is UGA’s principal investigator for Georgia CTSA, which received a $51 million National Institutes of Health statewide grant.

The second Deals of the Year Award was presented to the National Science Foundation Engineering Research Center for Cell Manufacturing Technologies (CMaT), which received a $20 million grant. CMaT is a federally funded consortium based at the Georgia Institute of Technology and designed to lower the cost and improve the reliability and safety of advanced cell therapies for chronic diseases like heart disease and cancer. The UGA lead for CMaT is Steven Stice, director of the Regenerative Bioscience Center, Georgia Research Alliance Eminent Scholar and D.W. Brooks Distinguished Professor in the College of Agricultural and Environmental Sciences.

Stice also accepted an Innovation Award for ArunA Biomedical, a biotechnology company he founded. ArunA Biomedical are experts in the design and scaling of a new class of cell-free biologic therapeutics and neural-specific drug delivery systems to treat central nervous system injury and neurodegenerative disorders. The Innovation Award honors those who are forging new ground by thinking outside traditional paradigms to create unique technology.

The Center for Tropical & Emerging Global Diseases received a Community Award, presented to those whose contributions to Georgia’s life sciences community are worthy of special recognition. Directed by Dennis Kyle, CTEGD is one of the largest international centers of research focused on diseases of poverty common to undeveloped and poor regions of the world. CTEGD researchers work on diseases that afflict hundreds of millions of people around the globe, including malaria, schistosomiasis, African sleeping sickness, Chagas disease, cryptosporidiosis, toxoplasmosis, leishmaniasis and filariasis.

Originally published at https://ugaresearch.uga.edu/uga-receives-life-sciences-industry-awards-from-georgia-bio/

Visiting Scholar: Elvis Ofori Ameyaw

 

scholar Elvis Ameyaw

Elvis Ofori Ameyaw is a Fulbright Scholar visiting M. Belen Cassera‘s laboratory in the department of molecular biology and biochemistry. He is a senior lecturer, Head of the Department of Biomedical Sciences and the Vice-Dean of the School of Allied Health Sciences in the College of Health and Allied Sciences at the University of Cape Coast in Ghana.

Dr. Ameyaw holds a B. Pharm and Ph.D. in Pharmacology. His research focuses on natural product drug discovery for infectious, in particular, malaria and Leishmania, and inflammatory diseases. At the University of Georgia, he is using in vitro techniques to screen some natural products isolates from plants that are traditionally used to treat malaria in Ghana.

“UGA is globally known for excellent research and education and my host scientist, Prof. M. Belen Cassera has created an envious and reputable niche in natural product research,” said Dr. Ameyaw.

The availability of seminars and other opportunities to interact with leading scientists also factored into Dr. Ameyaw’s decision to come to UGA.

“The research staff at UGA are very supportive and willing to share ideas.” said Dr. Ameyaw.

Athens reminds him of the college town of Cape Coast where he resides and works in Ghana.

“The city makes me feel at home away from home.”

Read more about Dr. Cassera’s natural products research.

UGA Researcher Seeks to Unlock Secrets of Malaria Parasite

malaria parasites
Super-resolution microscopy showing malaria parasites infecting human red blood cells. Image credit: Muthugapatti Kandasamy, Biomedical Microscopy Core

Vasant Muralidharan and his research team at the University of Georgia’s Center for Tropical and Emerging Global Diseases are making great strides in understanding how the malaria parasite hijacks red blood cells to cause disease but many of the parasite’s strategies remain elusive.  A new $1.875 million grant from the National Institutes of Health will allow them to continue this research.

Malaria is a parasitic disease that infects nearly 220 million people and kills nearly half a million people every year. Almost all the deaths occur in young children and primarily in sub-Saharan Africa. The parasite Plasmodium falciparum invades human red blood cells which directly leads to malaria symptoms that include headaches, muscle pain, periodic fevers with shivering, severe anemia, trouble breathing, and kidney failure. The parasite can also cause the most severe forms of malaria, such as cerebral malaria which can lead to brain damage, coma and death, and placental malaria, which occurs in pregnancy and can be life-threatening to both the mother and fetus.

Complete control of the infected red blood cell is required for parasites to grow and spread. The malaria parasite remodels the host cell by exporting hundreds of parasite proteins across numerous membranes that transform all aspects of infected red blood cells to suit its needs. The export of these proteins by P. falciparum to the host red blood cells is a unique parasite-driven process that is associated with many of the clinical manifestations of malaria, including death. The mechanisms which these proteins are exported are unknown.

“Exported proteins, many of them absolutely essential for the growth of the parasite, are recognized and sorted throughout the trafficking process by dedicated machinery that we have only now begun to understand,” said Muralidharan, assistant professor in the department of cellular biology.

His lab hopes to reveal unique protein trafficking mechanisms of P. falciparum that may be targets for antimalarial drug development.

 “We expect that this project will significantly advance our understanding of the protein export pathway in P. falciparum and how key decisions are made within the parasite that usher exported proteins to their site of action in the infected red blood cells,” concluded Muralidharan.

National Institutes of Health Award R01 AI130139 “Elucidating the trafficking mechanisms of effector proteins to the Plasmodium infected red blood cell.”

Trainee Spotlight: Karla Márquez Nogueras

trainee Karla Márquez Nogueras

NIH T32 Trainee Karla M. Márquez Nogueras is in her 4th year of graduate training in Silvia Moreno‘s laboratory. Before entering the Ph.D. program at UGA, she taught for a semester at Turabo University in Puerto Rico, teaching undergraduate courses like Introduction to Microbiology and Human Anatomy. She has a Bachelor’s degree in Industrial Microbiology and a Master’s in Science where she focused on generating renewable energy systems using methane generated by anaerobic microbial communities.

Karla’s research focus

Karla’s project focuses on calcium signaling in Toxoplasma gondii. Calcium is a universal signal molecule and very little is known about calcium signaling in T. gondii, even considering that all steps of the parasite’s lytic cycle are regulated by calcium. Calcium is highly regulated by Toxoplasma, specially upon exit from host cells and the surrounding calcium changes from very low levels inside the host cell to the high concentration found in the extracellular environment. In order to shed light into the mechanisms involved and to discover the molecules involved they are studying two key aspects: the calcium channels that could be responsible for calcium entry into the cytosol and the calcium binding proteins that could regulate them.

“When I first entered grad school my research goals were different,” said Karla. “During my rotation in Dr. Moreno’s lab, I became fascinated by the biology of Toxoplasma and by how little is known about calcium signaling in T. gondii. As a scientist, I became very curious and interested in finding more about these signaling pathways and I decided to change my research focus.”

Trainee capstone experience

Each T32 trainee is provided with the opportunity to complete a capstone experience at the end of their fellowship. This experience allows for an extended visit to a collaborator’s laboratory or travel to a scientific meeting where they present their research and interact with colleagues.

“I was invited to the University of Puerto Rico to present my research project and discuss graduate and fellowship opportunities available at UGA. I would be presenting at an undergraduate event organized by the University.”

In addition, she would like to visit the laboratory of Dr. Ivana Kuo at Northwestern University to study the function of two TRP channels that Karla is characterizing. Dr. Kuo uses lipid layers and regular patch-clamp to characterize intracellular and plasma membrane channels. Using this system Karla hopes to understand the physiology of these channels that are important for calcium signaling in T. gondii.

T32 Fellowship helps trainees achieve their goals

“The fellowship will provide me with the necessary experience and opportunities for me to develop the skills to become a better scientist.”

Karla would like to go back to Puerto Rico and establish her own research lab. She would like to have the opportunity to train and give students the same opportunities that were given to her during her Ph.D. training.

“All the skills gained throughout this two years will prepare me for my ultimate goal which is to have my own research lab.”

Learn more about our trainee fellowship programs.

Trainee Spotlight: Molly Bunkofse

trainee Molly Bunkofse

NIH T32 trainee Molly Bunkofse, a Ph.D. student in Rick Tarleton‘s laboratory, is originally from Illinois and I obtained my BA in Biology from a small, liberal arts college called Augustana, which is located in Rock Island, IL.

Molly’s research focus

Molly’s project focuses on the host CD8+ T cell response that is generated against flagellar proteins from the parasite Trypanosoma cruzi and exploring how these responses might be enhanced.

“I chose this research focus because I have always been interested in the host immune response to pathogens and especially pathogens that are able to escape the immune response and persist, such is the case in T. cruzi infection.”

Trainee capstone experience

Each T32 trainee is provided with the opportunity to complete a capstone experience at the end of their fellowship. This experience allows for an extended visit to a collaborator’s laboratory or travel to a scientific meeting where they present their research and interact with colleagues.

“For my capstone experience, I’d like to work in South America where Chagas disease is endemic, perhaps with one of our collaborators that works with human patients infected with T. cruzi.”

T32 fellowship helps trainees achieve their goals

“I think that the T32 fellowship will provide me with new opportunities to develop my research and skills as a scientist. The experiences and training will enable me to become a well-rounded scientist that can think critically and logically approach a question/problem.”

Molly hopes to continue her research in a government laboratory after graduation.

Trainee Spotlight: Ruby Harrison

trainee Ruby Harrison

NIH T32 trainee Ruby Harrison is a co-advised by Drs. Michael Strand and Mark Brown in the UGA Department of Entomology. She received a Bachelor’s of Science in Entomology from the University of Wisconsin-Madison in 2012 and lived in Madison an additional two years working with mosquitoes as a research assistant. Before coming to UGA to begin my doctoral studies, she spent a year in Gabon, Africa, working as a tropical ecology field technician.

Ruby’s research focus

Ruby studies mosquito-microbiome interactions. Currently, she is investigating the influence of the gut microbiome on mosquito reproductive processes. She also plans to begin exploring the role of the mosquito microbiome in deterring pathogen infection in the very near future.

“I chose this research focus because I was inspired by the research of a former graduate student of Dr. Strand’s, Dr. Kerri Coon. Kerri pioneered fascinating work on the influence of the microbiota on development in mosquitoes in the immature (larval) stage,” said Ruby. “I saw an opportunity to extend her work, to observe if the same bacterial signal essential to larval development is recapitulated in any way in the adult stage.”

More broadly, she sees insect-microbe interactions as a promising field which may offer new solutions for mosquito population control and reduction of pathogen transmission.

NIH T32 Fellowship helps trainees achieve their goals

Ultimately, Ruby hopes to build a career as a vector biologist. For the capstone experience provided by the NIH T32 Training Grant, she is interested in returning to francophone West or Central Africa to work with mosquitoes in the field.

“I am truly grateful to receive the T32 pre-doctoral training fellowship, which presents me the opportunity to interact more closely with the CTEGD, opens doors for possible collaboration, and will help me to pursue my research goals,” said Ruby.

An ancient bacterial protein complex in human malaria parasites is essential for parasite growth

Vasant Muralidharan and Anat Florentin

Several species of Plasmodium parasites cause malaria in humans and results in nearly 450,000 deaths annually. The deadliest of these species is Plasmodium falciparum. Unfortunately, it is also drug resistance to many of the currently available treatments. Vasant Muralidharan, assistant professor in the department of cellular biology, and his research group at The Center for Tropical and Emerging Global Diseases at The University of Georgia reported on an essential protein in hopes of identifying new drug targets.

Plasmodium parasites contain an organelle known as the apicoplast that evolved via the endosymbiosis of a red alga. The apicoplast produces several essential metabolites required for parasite growth and survival. Therefore, drugs that target the apicoplast are clinically effective. However, there is still not a lot known about this organelle. Understanding the function, structure, and biogenesis of the apicoplast provides a gold mine of antimalarial drug targets.

The role of Clp proteins in Plasmodium apicoplast

Clp (Caseinolytic Proteases) are conserved prokaryotic proteins that serve a wide variety of biological functions in bacteria, the evolutionary ancestors of the apicoplast. Several Clp proteins have been reported to localize in the apicoplast of the parasite but their biological functions were unknown.

The research team used different genetic tools to conditionally inhibit the function of various apicoplast-Clp proteins. “It is similar to understanding the role of a single card in holding up a house of cards by removing it from the structure,” said Muralidharan.

Their data show that the Clp chaperone PfClpC is essential for parasite viability and that its inhibition resulted in morphological defects, and loss of the apicoplast. They also revealed that the chaperone activity is required to stabilize a Clp Protease, PfClpP, suggesting that, similar to bacteria and plants chloroplasts, these two proteins form a proteolytic complex. These data may be relevant to the function of bacterial and plant Clp complexes. “Our findings shed light on the biological roles of the apicoplast Clp Proteins and their involvement in apicoplast replication,” said Dr. Anat Florentin, lead author on the study.

Significance of the findings

The role that bacterial Clp proteins play in cell division, stress response and ability to cause disease have placed them at the center of several drug discovery programs. The new understanding of Clp proteins in Plasmodium provides an avenue for drug development in malaria in which highly active antibacterial compounds can be repurposed as effective anti-malarial agents.

 

An online version of this study is available: A. Florentin,  D.W. Cobb, J.D. Fishburn, M. J. Cipriano, P.S. Kim, M.A. Fierro, B. Striepen, V. Muralidharan. 2017. PfClpC is an essential Clp chaperone required for plastid integrity and Clp protease stability in Plasmodium falciparum. Cell Reports 21, 1 – 11. http://dx.doi.org/10.1016/j.celrep.2017.10.081